Home > Rheumatology > EULAR 2020 > Psoriatic Arthritis > Secukinumab monotherapy as efficient as adalimumab

Secukinumab monotherapy as efficient as adalimumab

Main trial data from the head-to-head EXCEED trial showed that secukinumab monotherapy for biologic-naïve patients with active psoriatic arthritis is at least as efficacious as adalimumab monotherapy and provides higher responses on skin endpoints [1,3].

The EXCEED trial was a phase 3b study of patients with active psoriatic arthritis and an inadequate response or intolerance to conventional disease-modifying anti-rheumatic drugs (DMARDs). The trial compared the efficacy and safety of secukinumab and adalimumab as first-line biologic monotherapy through 52 weeks, with a musculoskeletal primary endpoint. The results were presented by Prof. Iain McInnes (University of Glasgow, United Kingdom), and simultaneously published in *The Lancet* [1,2].

Participants (n=853) were randomised to secukinumab 300 mg/week at weeks 0-4 and every 4 weeks thereafter (n=426) or adalimumab 40 mg subcutaneous ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on